LiDCO : to present at Mello London, 2019

LiDCO Group Plc

('LiDCO' or the 'Company')

LiDCO to present at Mello London, 2019

LiDCO (AIM: LID), the hemodynamic monitoring company, is pleased to announce that the Company will be attending the Mello London, 2019 investor conference taking place on Tuesday 12th & Wednesday 13th November 2019 to be held at the Clayton Hotel Chiswick, Chiswick High Road, London, W4 5RY.

Matt Sassone, Chief Executive Officer of LiDCO, will be presenting to delegates on Tuesday 12th November 2019.

For further information on the Mello London conference, please visit the event website https://melloevents.com/

For further information, please contact:

LiDCO Group Plc	www.lidco.com
Matt Sassone (CEO)	Tel: [phone]
Tim Hall(CFO)
finnCap	Tel: [phone]
Geoff Nash / Hannah Boros (Corporate Finance)
Andrew Burdis (Corporate Broking)
Walbrook PR Ltd	Tel: [phone] [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.

Increasingly clinical studies have shown that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed originally at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOunity:a hemodynamic monitor that combines the full suite of LiDCO technology (non-invasive, minimally invasive and calibrated technologies) into one platform. Designed to have the flexibility to adapt to a patient's changing acuity, the product enables clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring.LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapidprovides:

· early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

· quantification of hemodynamic response guidance on effective delivery of fluids to ensure the right amount at the right time

The software incorporated into LiDCOrapidallows the LiDCOrapidmonitor to co-display Medtronic's level of consciousness parameter ('BIS^TM')* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This addresses a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors.

LiDCOview: an easy-to-use graphical display of historical LiDCOplusand LiDCOrapidhemodynamic data.

*BIS^TMand Bispectral Index are trademarks of Medtronic registered in the US and foreign countries.

**CNAP^TM is a trademark of CNSystems Medizintechnik AG.

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USAand through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's headquarters are in London and its shares are traded on AIM.